Toll Free: 1-888-928-9744

ATLAB Pharma SAS - Product Pipeline Review - 2015

Published: May, 2015 | Pages: 22 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

ATLAB Pharma SAS - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'ATLAB Pharma SAS - Product Pipeline Review - 2015', provides an overview of the ATLAB Pharma SAS's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of ATLAB Pharma SAS's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of ATLAB Pharma SAS including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of ATLAB Pharma SAS's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the ATLAB Pharma SAS's pipeline products

Reason to Buy

- Evaluate ATLAB Pharma SAS's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of ATLAB Pharma SAS in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the ATLAB Pharma SAS's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of ATLAB Pharma SAS and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of ATLAB Pharma SAS
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of ATLAB Pharma SAS and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2 List of Tables 3 List of Figures 3 ATLAB Pharma SAS Snapshot 4 ATLAB Pharma SAS Overview 4 Key Information 4 Key Facts 4 ATLAB Pharma SAS - Research and Development Overview 5 Key Therapeutic Areas 5 ATLAB Pharma SAS - Pipeline Review 6 Pipeline Products by Stage of Development 6 Pipeline Products - Monotherapy 7 ATLAB Pharma SAS - Pipeline Products Glance 8 ATLAB Pharma SAS - Clinical Stage Pipeline Products 8 Phase II Products/Combination Treatment Modalities 8 ATLAB Pharma SAS - Early Stage Pipeline Products 9 Preclinical Products/Combination Treatment Modalities 9 ATLAB Pharma SAS - Drug Profiles 10 ATL-101 10 Product Description 10 Mechanism of Action 10 R&D Progress 10 ATL-201 12 Product Description 12 Mechanism of Action 12 R&D Progress 12 ATL-301 13 Product Description 13 Mechanism of Action 13 R&D Progress 13 ATL-302 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 ATLAB Pharma SAS - Pipeline Analysis 15 ATLAB Pharma SAS - Pipeline Products by Target 15 ATLAB Pharma SAS - Pipeline Products by Route of Administration 16 ATLAB Pharma SAS - Pipeline Products by Molecule Type 17 ATLAB Pharma SAS - Pipeline Products by Mechanism of Action 18 ATLAB Pharma SAS - Recent Pipeline Updates 19 ATLAB Pharma SAS - Locations And Subsidiaries 20 Head Office 20 Other Locations & Subsidiaries 20 Appendix 21 Methodology 21 Coverage 21 Secondary Research 21 Primary Research 21 Expert Panel Validation 21 Contact Us 21 Disclaimer 22
List of Tables
ATLAB Pharma SAS, Key Information 4 ATLAB Pharma SAS, Key Facts 4 ATLAB Pharma SAS - Pipeline by Indication, 2015 5 ATLAB Pharma SAS - Pipeline by Stage of Development, 2015 6 ATLAB Pharma SAS - Monotherapy Products in Pipeline, 2015 7 ATLAB Pharma SAS - Phase II, 2015 8 ATLAB Pharma SAS - Preclinical, 2015 9 ATLAB Pharma SAS - Pipeline by Target, 2015 15 ATLAB Pharma SAS - Pipeline by Route of Administration, 2015 16 ATLAB Pharma SAS - Pipeline by Molecule Type, 2015 17 ATLAB Pharma SAS - Pipeline Products by Mechanism of Action, 2015 18 ATLAB Pharma SAS - Recent Pipeline Updates, 2015 19 ATLAB Pharma SAS, Other Locations 20



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify